Hardy Michaël, Michaux Isabelle, Lessire Sarah, Douxfils Jonathan, Dogné Jean-Michel, Bareille Marion, Horlait Geoffrey, Bulpa Pierre, Chapelle Celine, Laporte Silvy, Testa Sophie, Jacqmin Hugues, Lecompte Thomas, Dive Alain, Mullier François
Université catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium.
Université catholique de Louvain, CHU UCL Namur, Anesthesiology Department, Namur Thrombosis and hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Yvoir, Belgium.
Data Brief. 2020 Dec;33:106519. doi: 10.1016/j.dib.2020.106519. Epub 2020 Nov 10.
This data article accompanies the manuscript entitled: "Prothrombotic Disturbances of hemostasis of Patients with Severe COVID-19: a Prospective Longitudinal Observational Cohort Study" submitted to by the same authors. We report temporal changes of plasma levels of an extended set of laboratory parameters during the ICU stay of the 21 COVID-19 patients included in the monocentre cohort: CRP, platelet count, prothrombin time; Clauss fibrinogen and clotting factors II, V and VIII levels, D-dimers, antithrombin activity, protein C, free protein S, total and free tissue factor pathway inhibitor, PAI-1 levels, von Willebrand factor antigen and activity, ADAMTS-13 (plasma levels); and of two integrative tests of coagulation (thrombin generation with ST Genesia) and fibrinolysis (global fibrinolytic capacity - GFC). Regarding hemostasis, we used double-centrifuged frozen citrated plasma prospectively collected after daily performance of usual coagulation tests. Demographic and clinical characteristics of patients and thrombotic and hemorrhagic complications were also collected from patient's electronic medical reports.
这篇数据文章附属于同一组作者提交的题为《重症 COVID-19 患者止血的血栓前状态紊乱：一项前瞻性纵向观察队列研究》的手稿。我们报告了单中心队列中 21 例 COVID-19 患者在重症监护病房（ICU）住院期间一系列扩展实验室参数的血浆水平随时间的变化：CRP、血小板计数、凝血酶原时间；Clauss 纤维蛋白原以及凝血因子 II、V 和 VIII 水平、D-二聚体、抗凝血酶活性、蛋白 C、游离蛋白 S、总组织因子途径抑制物和游离组织因子途径抑制物、PAI-1 水平、血管性血友病因子抗原和活性、ADAMTS-13（血浆水平）；以及两项凝血综合检测（使用 ST Genesia 进行凝血酶生成检测）和纤维蛋白溶解检测（整体纤维蛋白溶解能力 - GFC）。关于止血，我们使用了在每日进行常规凝血检测后前瞻性收集的双离心冷冻枸橼酸盐血浆。患者的人口统计学和临床特征以及血栓形成和出血并发症也从患者的电子病历报告中收集。
